CDKN2A and breast cancer: In the discovery phase using 48 breast cancer cases and 47 controls, we found that increased pre-treatment p16INK4a mRNA expression was associated with 1.40-fold increased risk of breast cancer (OR = 1.40; 95%CI: 1.21, 1.68; p < 0.001).